With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...
A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.
Opens in a new tab or window More thyroid cancers were detected soon after starting a GLP-1 receptor agonist than other diabetes drugs, a secondary analysis of a target trial emulation of a ...
Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders.
Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...
Time for your weekly edition of the Defector Funbag. Got something on your mind? Email the Funbag. And buy Drew’s book, The ...
The analysis included 98,147 GLP-1 RA users and approximately 2.49 million DPP-4i users, with a median follow-up ranging from 1.8 to 3 years. HealthDay News — Glucagon-like peptide 1 receptor ...
T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...
Scientists find Ozempic may treat cancer, Alzheimer's and more. Is it hype or truly a "wonder drug?"
For GLP-1 receptors, it’s GLP-1. Ozempic, or semaglutide, is a GLP-1 agonist, meaning its molecules mimic the structure of GLP-1, binding to its receptor like a counterfeit key someone’s ...
Some outcomes, like reduced risk of cardiovascular disease and increased chance of nausea, were expected. But others took ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback